Needle-based Confocal Laser Endomicroscopy Guided For Lung Cancer Diagnosis: A Randomized Controlled Trial


About this study

The purpose of this study is to compare per pass diagnostic yield of different numbers of sequential needle passes (ROSE) and the procedure duration needed to obtain a contributive TBNA sample with ROBOTIC-guided TBNA to that of ROBOTIC-guided nCLE in PPNs.



Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • 18 years of age.
  • Suspected or tissue proven lung tumor and/or malignant peripheral/hilar lymph nodes.
  • Nodule size in CT between 8mm and 30 mm (largest dimension).
  • Ability to understand and willingness to sign a written informed consent and HIPAA consent document.

Exclusion Criteria:

  • Inability or non-willingness to provide informed consent.
  • Inability to comply with the study protocol.
  • Patients with known allergy for fluorescein or risk factors for an allergic reaction.
  • Use of beta-blocker within 24 hours before start of the bronchoscopic procedure.
  • Possible pregnant or lactating women.
  • Known allergy to fluorescein.
  • Patients with hemodynamic instability. 
  • Patients with refractory hypoxemia. 
  • Patients with therapeutic anticoagulant that cannot be held for an appropriate interval prior to the procedure.
  • Patients who are unable to tolerate general anesthesia according to the anesthesiologist.
  • Patient undergoing chemotherapy.                            
  • Pregnant or breast feeding.

Intra-operative Exclusion/Stopping Criteria:

  • The lesions are unable to be localized/confirmed by bronchoscopy.
  • The procedure will be terminated if the patient develops a significant procedural complication as determined by the treating physician.
  • The procedure will be terminated if the patient develops hemodynamic instability as determined by the treating physician.

Eligibility last updated 8/16/21.  Questions regarding updates should be directed to the study team contact.



Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Sebastian Fernandez-Bussy, M.D.

Open for enrollment

Contact information:

Clinical Studies Unit

(904) 953-2255

Rochester, Minn.

Mayo Clinic principal investigator

Janani Reisenauer, M.D.

Contact us for the latest status

Contact information:

Thoracic Surgery Research Unit

(877) 526-9172

More information


Publications are currently not available

Mayo Clinic Footer